Indivior PLC Gears Up for Key Investor Engagements This Fall

Indivior PLC (NASDAQ: INDV) has recently announced its participation in two important upcoming investor events, aimed at facilitating discussions on its innovative strategies in healthcare and furthering investor engagement.

The company’s leadership team, including Chief Executive Officer Joe Ciaffoni and Chief Financial Officer Ryan Preblick, will be present at the Morgan Stanley 23rd Annual Global Healthcare Conference, set to take place on September 8, 2025, in New York City. They will hold both one-on-one and group meetings throughout the day, providing a platform for direct investor interaction.

During this conference, Joe Ciaffoni will also join a fireside discussion scheduled for 9:15 AM ET. This discussion will be publicly accessible, offering a chance for investors and interested parties to gain insights into Indivior’s plans and ongoing developments in the field of opioid use disorder (OUD). This forthcoming discussion underscores Indivior's commitment to transparency and investor relations, catering to those seeking to understand more about the company's direction. Investors who wish to attend are encouraged to coordinate with their Morgan Stanley representatives.

The following day, September 9, 2025, Indivior will continue its investor outreach at the H.C. Wainwright 27th Annual Global Investment Conference, also in New York City. Similar to the previous event, Ciaffoni and Preblick will host additional meetings which are open to investors eager to explore Indivior's current and future initiatives. Interested parties are encouraged to reach out to their H.C. Wainwright representatives for scheduling.

Indivior is recognized as a leading global pharmaceutical company that focuses on creating treatments for opioid use disorder, amongst other health challenges. Its overall mission is to improve the lives of patients globally by ensuring they have access to evidence-based treatment for OUD, which has increasingly become a significant public health concern.

Headquartered in Richmond, Virginia, the company's innovative approach seeks to transform OUD from a national crisis into a recognized chronic disease that receives appropriate treatment. Committed to this vision, Indivior is also developing a range of new product candidates that build upon its existing portfolio of OUD treatments. With a workforce of over 1,000 employees, Indivior is proud to provide its services in over 30 countries worldwide.

To learn more about their initiatives and product offerings, interested individuals can visit Indivior's official website at www.indivior.com. For those who wish to keep updated on Indivior’s endeavors, the company is also active on LinkedIn, where they share valuable insights and updates.

As Indivior prepares for these significant investor events, the company looks forward to engaging with current and potential investors to shed light on its strategies and contributions to the healthcare sector. With the upcoming discussions set, stakeholders have ample opportunity to engage deeply with the organization’s advancements and future outlook in addressing one of today's most pressing health issues.